Cruise Fever |
Princess Cruises Raising $1 Million for the American Heart Association
Cruise Fever Dr. Kathy Magilato, MD, MBA, FACS is one of the few female cardiothoracic surgeons specializing in heart transplantation, heart failure, and mechanical/artificial heart technology. She is the director of the Women’s Cardiac Services at Saint John’s … |
Chemical pollution linked to infection, bladder cancer – Times of India
Chemical pollution linked to infection, bladder cancerTimes of IndiaGastrointestinal infections, typhoid, anemia, kidney and liver damage are some of the common health problems associated with chemical pollutants. Doctors say high levels of amine, a de…
Robot-assisted surgery may preserve kidney function – Manoramaonline
|
Robot-assisted surgery may preserve kidney function
Manoramaonline In a ground-breaking study, researchers at Henry Ford Hospital’s Vattikuti Urology Institute in Detroit, Michigan, found that patients who received robot-assisted partial nephrectomy to treat kidney cancer had minimal loss of kidney function – a … |
Kalam Wants Strengthening of Healthcare System – Outlook
|
Kalam Wants Strengthening of Healthcare System
Outlook That means a new liver they can create and if it happens we may enter a new world and India may be the pioneer.” Director of ILBS S K Sarin urged people to donate organs saying, “Organ donation and pledging is worthwhile at any age.” He narrated the … |
Standard Review for Gileads Oncology Candidate – Zacks.com
|
Standard Review for Gileads Oncology Candidate
Zacks.com The patients were refractory to both Roche’s (RHHBY) Rituxan (rituximab) and to chemotherapy inclusive alkylating-agent. A decision from the FDA is expected by Sep 11, 2014. Apart from iNHL, idelalisib is also being evaluated in other oncology … Gilead’s Idelalisib NDA accepted by US FDA for the treatment of refractory …MENAFN.COM |
More teens lack HSV-1 antibodies – ModernMedicine
More teens lack HSV-1 antibodiesModernMedicineAn increasing number of American adolescents lack herpes simplex virus (HSV) type 1 antibodies, making them more susceptible to genital herpes following sexual debut, according to a recent study in The Jour…
Agenus Inc. – "Are We Getting Closer to Curing Cancer With Checkpoint … – MarketWatch
|
Agenus Inc. – “Are We Getting Closer to Curing Cancer With Checkpoint …
MarketWatch Read the full blog post on TheChairmansBlog.com ( http://www.thechairmansblog.com/agenus/garo-armen/getting-closer-curing-cancer-checkpoint-antibodies/ ). About Agenus. Agenus Inc. is a biotechnology company working to develop treatments for … |
Erlanger Announces Appointment Of Asad Zaman, MHA, As Transplant Service … – The Chattanoogan
The Chattanoogan |
Erlanger Announces Appointment Of Asad Zaman, MHA, As Transplant Service …
The Chattanoogan … the overall operation of end-stage renal care in our region. As the region’s only kidney transplant program, Asad will focus on providing more outreach to surrounding communities and educating patients about their local option for kidney … |
Jahi McMath Case Renews Moral Debate Over Brain-Death Diagnoses – National Catholic Register
National Catholic RegisterJahi McMath Case Renews Moral Debate Over Brain-Death DiagnosesNational Catholic RegisterThe debate has been typified by neonatologist and pediatrician Dr. Paul Byrne, who for years has led a movement against the acceptance of…
Rexahn Pharma (RNN) Initiates Archexin Proof-of-Concept Study in RCC – StreetInsider.com (subscription)
|
Rexahn Pharma (RNN) Initiates Archexin Proof-of-Concept Study in RCC
StreetInsider.com (subscription) The Phase IIa Archexin proof-of-concept clinical trial is a multi-center study designed to evaluate the efficacy of Archexin in combination with everolimus (Afinitor®) to treat metastatic RCC patients and will be conducted in two stages. Stage 1 will … |